Brass Tacks: The Money Problem

Slides:



Advertisements
Similar presentations
Building a New Payment System: Stakeholder Perspectives on Principles and Elements Robert L. Broadway, FHFMA VP of Corporate Strategy, Bethesda Healthcare.
Advertisements

1 Palliative Care and Shared Decision-Making HOW TO BECOME AN INFORMED HEALTHCARE DECISION MAKER.
© 2014 American Orthotic & Prosthetic Association All rights reserved.
SAO Steve Barlow CMO SelectHealth September 2012.
Copyright 2014 ValueOptions. ® All rights reserved. Strengthening the Behavioral Health System through Alternative Payment Nancy Lane, Ph.D. Chief Executive.
Leading Age Maryland Annual Conference 2015 Maryland Healthcare and Aging Services Intersections Workshop Session F Wednesday, April 22, :45 – 3:45.
Tracey Moorhead President and CEO May 15, 2015 No Disclosures ©AAHCM.
Lukas Steinmann Mexico 10. June 2008 To your health: diagnosing the state of healthcare and the global private medical insurance industry.
1 The Case Management Approach October 11, 2012 International Centre, Mississauga, ON Suzanne Lepage Private Health Plan Strategist.
Joe Selby, MD MPH EBRI December 15, 2011 What Might Patient (Employee)- Centered Research Look Like?
Obesity Symposium-Ignite the fight against Obesity: Advocate’s Approach to Population Health Management September 26 th 2014 Pankaj Patel MD MSc Senior.
OUTLINE OF HEALTH CARE PLAN RICHARD R. SCHNEIDER, MD F.A.C.P., F.A.C.C.
THE HIT ADOPTIONINITIATIVE The George Washington University School of Public Health and Health Services The Institute for Health Policy at MGH/Partners.
Better, Smarter, Healthier: Delivery System Reform U.S. Department of Health and Human Services 1.
Community Paramedic Payment Reform December 2 nd,2015 Terrace Mall- North Memorial.
Measuring and Reporting Performance Data Through Health IT AHRQ Annual Meeting Wednesday September 26, 2007 A. John Blair, III, MD President, Taconic IPA.
NORTHERN NEW ENGLAND ACCOUNTABLE CARE COLLABORATIVE NNEACC 1 LD 1818 WORK GROUP David Wennberg August 9, 2012.
UNDERSTANDING THE ONCOLOGY CARE MODEL (OCM) 1 © 2016 Community Oncology Alliance.
All-Payer Model Update
The New World of Physician Payments
Comparative Effectiveness Research: Key Issues and Controversies
Home healthcare – an economic choice for the Health Service?
Value Based Payment Programs Quality Payment Program
MACRA UPDATE Presented by Judella Haddad-Lacle MD
How to Cure Your HIT Ailments and Managing Accountable Care
Alternative Payment Models in the Quality Payment Program
CDC’s 6|18 Initiative: Accelerating Evidence into Action American College of Preventive Medicine Utilizing the 6|18 Initiative to Address High Blood.
What’s Next for Maryland Hospitals HFMA Maryland Chapter
Outpatient Home Based Palliative Care
All-Payer Model Progression
IoT Health Slam December 2, 2016.
Optimizing Meds – Need for Systems Approach
Prospects for New Delivery Systems and Reimbursement Models
Bundled Payments: An Initiative of Payment Reform
Financial Analysis Of Electronic Health Records (EHR’s)
Health Insurance.
An Economic Perspective
Brass Tacks: HCT and the Money Problem
The Focus on Quality A Closer Look at a National Trend
“Next Generation of Connected Health”
Paying for Serious Illness Care Under a Global Budget: Opportunities and Challenges Anna Gosline, Senior Director of Health Policy and Strategic Initiatives,
MACRA: Using Data to Capture the Quality
ACO Population Health: Raising the Bar Along the Journey
Everyone counts: working together to tackle Delayed Transfers of Care
Networks and/or Provider-based care Financial Performance
Oncology Care Model 2.0 The Universal Payment Model in Oncology
BHCAG TCOC Discussion March 28, 2012 Meg Hasbrouck Vice President, Contracting and Reimbursement Mission We serve our communities by providing exceptional.
William Morgan, MD, Chief Clinical Officer,
Using an Episode-based payment model to improve oncology care
Population Health.
Provider and Member Education in Managed Care Pharmacy
Medicare and Hospitals
Accountable care organizations
Next steps in oncology payment reform
All-Payer Model Update
Kathy Clodfelter, MSN, MBA, RN, NE-BC
Component 1: Introduction to Health Care and Public Health in the U.S.
CalSWEC 2014: Aging Initiative Summit
Hospitals Role in The Accountable Marketplace
Payment Reform to Transform Advanced Illness Care
Applications of quality assurance to administration and managed care
Medicare: Risks and Opportunities for 2019
Designing new payment models for Medical Care: Version 2009 (PCMH) Presentation to The Medical Home Summit Bob Doherty Senior Vice President, Governmental.
TCPI Project Pathway: Session 8 of 8 Business Strategies Milestone #’s 18, 20, 21(specialty) 23, 25, 26 (primary care)
Pharmacy – Fully Insured versus Self Funding
[Group Name].
Delivering better value in the NHS
2019 MIPS Cost Performance Category
By: Andi Indahwaty Sidin A Critical Review of The Role of Clinical Governance in Health Care and its Potential Application in Indonesia.
Implications of MACRA for Community Health Centers
Presentation transcript:

Brass Tacks: The Money Problem R. Maziarz, MD AGFBT Meeting 10/20/2016

Financial Disclosures

Objectives Identify opportunities for research in improving value and emerging reimbursement models Summarize the predicted impact of MACRA and the Oncology Care Model Evaluate the CIBMTR 3-year survival metric and value

Baseline: Big Price Tags Bring Big Problems

Getting Down to Brass Tacks Brass tacks are a type of pin or nail, sometimes called a drawing pin. In colloquial English, the phrase to get down to brass tacks is an idiom that means to focus on essential details, such as measuring out the precise amount of an item for sale. Brass Tacks for the AGFBT = What’s the societal ROI? Value of HCT Emerging Reimbursement Models

Value= Health outcomes that matter to patient What is Value? Value proposition= Expensive, but potentially curative Value = Quality/Cost Value= Health outcomes that matter to patient Cost of Delivery Adapted from Porter 2015

Understanding the Components Health Outcomes that matter to patients Survival – OS and PFS Self-reported QOL Return to work/normal Financial Toxicity Cost of Care Delivered Claims data analysis Evidence-based care Unnecessary waster HSR Working Groups, PCORI Efforts HSR/HE SIG Efforts Research, Guidelines AGFBT Subgroup

Defining Waste American Society for Quality (ASQ) = “healthcare services that do not add value or improve patient outcomes”

Can we identify how much waste exists in HCT? Starting Points: Milliman Estimate of Auto and Allo HCT costs PMPM = $3.33 2010 LifeLink data total average monthly spend PMPM = $320 $750 Billion in Waste 3.33 320 = 𝑥 750,000,000,000 = $7,804,687,500

$7,804,687,500 Seems Rather Dramatic Ok - Let’s assume HCT is dramatically better than average $7,804,687,500∗.01=$78,046,875 Average Transplant Episode Charges = ~$1 Million $78,046,875 $1,000,000 =78 Do we waste the equivalent of 78 transplants per year?

Categories of Waste Administrative Complexity Failures of Care Delivery Adverse Events, HAIs, Misdiagnosis Failures of Care Coordination Readmission, Decline in Functional Status Overtreatment Defensive medicine, provider preference, futile care Administrative Complexity Unstandardized forms and procedures Pricing Failures Above market value for no reason Fraud and Abuse Health Affairs (2012)

""Health Policy Brief: Reducing Waste in Health Care," Health Affairs, December 13, 2012. http://www.healthaffairs.org/healthpolicybriefs/

Can we complete the matrix for HCT? No, but we can guess… Category Low Midpoint High Failures of Care Delivery X Failures of Care Coordination Overtreatment ? Administrative Complexity Pricing Failures

Other Potential Categories HCT-specific care practices: Labs Medications LOS variation Variation in patient selection Variation in donor selection Care-setting variation (IP vs OP) Time to consult Time to transplant Examination of Outliers – Commonalities?

IOM Recommendations on Countering Waste “ICU clinicians have 180 activities per patient per day” Improve providers' capacity to collect and use digital data to advance science and improve care. Involve patients and their families or caregivers in care decisions. Use clinical practice guidelines and provider decision support tools to a greater extent. Promote partnerships and coordination between providers and the community to improve care transitions. Realign financial incentives to promote continuous learning and the delivery of high-quality, low-cost care. Improve transparency in provider performance, including quality, price, cost, and outcomes information. IOM, September 2012

New Reimbursement Models: MACRA, MIPS, OCM

The Main Idea: Incentivize MD Care Choices CMS-created systems of adjusting MD payment based on quality and cost MACRA – goes into effect in 2017 MIPS and other measures of ‘quality’ Oncology Care Model and episode payments (cardiac, knee/hip) can substitute as Alternative Payment Methods Many commercial/government payers outside of CMS adopting OCM Tracks cost of care in 6 months after initial outpatient treatment Compares against historical baseline; MDs win/lose based on the Δ Supposed to have exceptions for ‘breakthrough therapies’

Oncology Pathways Summary Pathways developed from national guidelines Take into account: Clinical benefit Toxicity Cost

Oncology Pathways Benefits: Based on established guidelines, enhanced reimbursement

Oncology Pathways Drawbacks: Prescribed pathways don’t necessarily allow physician subjective judgment; different pathways with different payers

Oncology Pathways Applicability to HCT: Would require HCT community input with payers on a regular basis. Suggestion—patients selected for a pathway automatically preauthorize for care

Oncology Pathways Example

Reimbursement Model Survey Model Name Summary Benefits Drawbacks Applicability to HCT? Oncology Pathways Pathways developed from national guidelines taking into account clinical benefit, toxicity and cost Based on established guidelines, enhanced reimbursement Prescribed pathways don’t necessarily allow physician subjective judgment; different pathways with different payers Would require HCT community input with payers on a regular basis. Suggestion—pts selected for a pathway automatically preauthorize for care

Oncology Pathways References BCBS Pathway experience, n= 4,713 $10.3 million in savings http://www.ncbi.nlm.nih.gov/pubmed/23943896 Oncology Pathways—Preventing a Good Idea from Going Bad http://oncology.jamanetwork.com/article.aspx?articleid=2485187

CMS Oncology Care Model Multi-Payer program run through CMS PBPM payment for managing care (Medicare FFS) OCM follows 6 month episodes of care costs; triggered by initial chemo claim Performance-based payment paid out dependent on quality measure achievements Incentive to lower the total cost of care and improve QOL

Oncology Care Model References http://jop.ascopubs.org/content/11/2/114.long

Impact of MACRA/OCM on HCT Team sports (like HCT) do not fit neatly into MACRA blueprint Will patients who need transplant or other high-cost care become undesirables? Initial years have limited risk, but substantial dollars in play by 2020